⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9686986 | 1.00 | — | — | |
| SCHEMBL14972809 | 0.98 | NAMPT (0.47) | — | |
| SCHEMBL28943338 | 0.98 | NAMPT (0.47) | — | |
| SCHEMBL29597368 | 0.98 | NAMPT (0.47) | — | |
| SCHEMBL3972493 | 0.86 | — | — | |
| SCHEMBL2834476 | 0.86 | — | — | |
| SCHEMBL9943877 | 0.86 | — | — | |
| SCHEMBL1311913 | 0.84 | — | — | |
| SCHEMBL980488 | 0.77 | — | — | |
| SCHEMBL30881494 | 0.76 | NAMPT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4648753-B1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008779-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMA (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4648753-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250288563-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2025-09-18 | — | — | US | disclosed |
| US-20250248981-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2025-08-07 | — | — | US | disclosed |
| EP-3880197-B9 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12319693-B2 | Crystalline forms of CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250051326-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2025-02-13 | — | — | US | disclosed |
| US-12186306-B2 | Methods of treatment for cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-07 | — | — | US | disclosed |
| US-20210047350-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| US-20210047323-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| US-20210047323-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| WO-2020102346-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-15 | — | — | US | disclosed |
| EP-0307078-B1 | QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1992-08-26 | — | — | EP | disclosed |
| US-5051508-A | Antisecretory agents and enzyme inhibitors as antiulcer agents | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1991-09-24 | — | — | US | disclosed |